Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

Tanshinone IIA and hepatocellular carcinoma: A potential therapeutic drug

Because of its high prevalence and poor long-term clinical treatment effect, liver disease is regarded as a major public health problem around the world. Among them, viral hepatitis, fatty liver, cirrhosis, non-alcoholic fatty liver disease (NAFLD), and autoimmune liver disease are common causes and...

Full description

Bibliographic Details
Main Authors: Hu Li, Pengbo Hu, Yajun Zou, Lijuan Yuan, Yucheng Xu, Xiaohui Zhang, Xiaoyan Luo, Zhiqiang Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
Hepatocellular carcinoma
tanshinone IIA
liver fibrosis
nonalcoholic fatty liver disease (NAFLD)
MAPK
rapamycin (mTOR)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1071415/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1071415/full

Similar Items